Domperidone–Ciprofloxacin QT Prolongation Risk
Domperidone is associated with QT interval prolongation and serious ventricular arrhythmias. [1]
Both domperidone and ciprofloxacin have QT-related risk labeling. [1][2]
Coadministration of domperidone with QT-prolonging medicines is contraindicated by European labeling, which supports avoiding the combination when possible. [1][3]
Guideline and Regulatory Recommendations
Domperidone is contraindicated when co-administered with QT-prolonging medicines. [1][3]
Domperidone is contraindicated when co-administered with potent CYP3A4 inhibitors. [1][3]
Ciprofloxacin labeling advises avoidance in patients with known QT prolongation or torsade de pointes risk factors and notes QT prolongation as a risk. [2]
Medication Selection Algorithm
- Avoid the combination (domperidone + ciprofloxacin) when feasible based on domperidone’s QT-prolonging medicines contraindication. [1][3]
- Select alternative antiemetic options that do not carry the same QT-prolonging contraindication status as domperidone in the product safety communications. [1][3]
- Select alternative antibiotics when clinically appropriate, avoiding ciprofloxacin when QT-prolongation risk is present or when QT-prolonging drug avoidance is required by the domperidone contraindication. [1][2]
Key Evidence Supporting This Recommendation
- Regulatory safety reviews confirm a small increased risk of serious cardiac adverse reactions with domperidone, including QTc prolongation and arrhythmias. [1]
- Domperidone product information highlights increased risk with concurrent QT-prolonging drugs. [4]
- Ciprofloxacin labeling reports QT prolongation and torsade de pointes risk and specifies avoidance in patients with QT prolongation or significant risk factors. [2]
Monotherapy vs Combination Therapy
- When a QT-prolonging medicines contraindication exists for one agent (domperidone), combination therapy with another QT-risk agent (ciprofloxacin) should be avoided in favor of monotherapy with lower QT-risk alternatives when possible. [1][3][2]
Initiation Thresholds and Clinical Situations
Ciprofloxacin should be avoided in patients with known QT prolongation and torsade de pointes risk factors as specified in the prescribing information. [2]
Domperidone should not be used in patients with underlying cardiac conduction disease or other conditions that increase arrhythmia risk, and it should be avoided with QT-prolonging co-medications. [1][3][4]
Common Pitfalls to Avoid
- Using domperidone alongside other QT-interacting medications without ECG and electrolyte risk assessment. [4][1]
- Prescribing ciprofloxacin in patients with baseline QT prolongation or other torsade risk factors. [2]
Targets and Monitoring Goals When QT-Risk Therapy Is Unavoidable
No domperidone–ciprofloxacin-specific QT threshold is provided in the cited labeling sources. [1][2]
In higher-risk patients, prevention strategies for torsade de pointes emphasize correction of electrolyte abnormalities and discontinuation of the offending QT-risk drug when ECG signs of impending torsade develop. [5]
Direct Answer
Yes. Domperidone and ciprofloxacin should generally be avoided together due to the QT-related risk labeling for both drugs and domperidone’s contraindication with QT-prolonging medicines. [1][3][2]